RT Journal Article
SR Electronic
T1 Peripheral neurotoxicity of pegylated interferon alpha
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP 781
OP 785
DO 10.1212/01.wnl.0000233889.07772.76
VO 67
IS 5
A1 Briani, C.
A1 Chemello, L.
A1 Zara, G.
A1 Ermani, M.
A1 Bernardinello, E.
A1 Ruggero, S.
A1 Toffanin, E.
A1 Gatta, A.
A1 Battistin, L.
A1 Cavalletto, L.
YR 2006
UL http://n.neurology.org/content/67/5/781.abstract
AB Objective: To assess whether pegylated interferon alpha (PEG-IFNα) may induce peripheral neuropathy or antibodies to peripheral nerve antigens in patients with hepatitis C virus (HCV) infection. Methods: We studied 52 patients with HCV (38 men, 14 women; mean age 44.6 ± 10.6 years) treated with IFNα. Before therapy (T0), patients underwent quantitative viral RNA determination, HCV genotype analysis, and neurologic and electrophysiologic evaluation. At the end (T1) and after therapy (T2), patients were neurologically and electrophysiologically re-evaluated. Antibodies to gangliosides and sulfatides were assayed by ELISA at T0 and T1. Twenty-three patients with HCV with comparable age, viral load, and genotype, not treated with IFNα, were studied as controls. Results: Seven patients (six in IFNα, one control) had peripheral neuropathy at recruitment. No significant differences in the electrophysiologic measures were detected between T0 and T1 (repeated-measures analysis of variance [ANOVA]) in any of the 52 patients or in those with neuropathy at T0. No changes were found at T2, independent of the viral response to treatment. Two patients, one with neuropathy, had antiganglioside antibodies at recruitment. Two patients, one not treated with IFNα, developed low antibody titers during follow-up, without symptoms or signs of neuropathy. Conclusions: Pegylated interferon alpha therapy was not associated with the occurrence (or worsening) of peripheral neuropathy or antibodies to peripheral nerve antigens in patients with hepatitis C virus.